Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Takeda, LegoChem research ADCs; Takeda later gains rights for multiple immuno-oncology targets in $411mm license deal

Executive Summary

LegoChem Biosciences Inc. and Takeda Pharmaceutical Co. Ltd. (through its Takeda Oncology/Millennium Pharmaceuticals unit) will together research and develop next-generation antibody-drug conjugates (ADCs) for cancer.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • ADMET
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register